2026 James Larkin: Medicine Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Medicine	120	3650	3414	361	346	629	126687

Overview

James Larkin is a researcher affiliated with the Royal Marsden NHS Foundation Trust in the United Kingdom. Their work spans several domains primarily within medicine, with a focus on oncology and related biomedical sciences.

Their research contributions are distributed across key fields of study including Medicine and Biochemistry, Genetics and Molecular Biology. Within these broader areas, they have concentrated on subfields such as Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Immunology, and Cancer Research.

Larkin's main topics of investigation include Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Renal cell carcinoma treatment, Melanoma and MAPK Pathways, Cancer Genomics and Diagnostics, Immunotherapy and Immune Responses, and Cutaneous Melanoma Detection and Management.

The scientist has published extensively, with frequent appearances in prominent scientific journals. Key publication venues include the Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer, Journal for ImmunoTherapy of Cancer, and ESMO Open.

Recent papers authored or co-authored by James Larkin demonstrate a focus on immunotherapy and cancer treatment strategies:

Immune checkpoint inhibitors in melanoma (2021, The Lancet)
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2022, Annals of Oncology)
Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition (2021, Cell)
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma (2022, Zurich Open Repository and Archive (University of Zurich))
Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic (2020, Annals of Oncology)

James Larkin frequently collaborates with other researchers in the field. Notable co-authors include Samra Turajlic, Paolo A. Ascierto, Georgina V. Long, Lisa Pickering, and Dirk Schadendorf, indicating involvement in collaborative studies and multi-author research projects.

Best Publications

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

9013
Citations
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Marco Gerlinger;Andrew J. Rowan;Stuart Horswell;James Larkin

8405
Citations
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

8404
Citations
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Robert J. Motzer;Bernard Escudier;David F. McDermott;Saby George

5870
Citations
Pembrolizumab versus Ipilimumab in Advanced Melanoma

Caroline Robert;Caroline Robert;Caroline Robert;Jacob Schachter;Georgina V. Long;Ana Arance

5794
Citations
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

4954
Citations
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine

J. Larkin;V. Chiarion-Sileni;R. Gonzalez;J.-J. Grob

3875
Citations
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi

2966
Citations
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Keith T. Flaherty;Caroline Robert;Peter Hersey;Paul Nathan

2534
Citations
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

James Larkin;Paolo A. Ascierto;Brigitte Dréno;Victoria Atkinson

2277
Citations
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Robert J. Motzer;Konstantin Penkov;John Haanen;Brian Rini

2208
Citations
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

J. B. A. G. Haanen;F. Carbonnel;C. Robert;K. M. Kerr

2173
Citations
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

Jeffrey Weber;Mario Mandala;Michele Del Vecchio;Helen J. Gogas

2152
Citations
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

K T Flaherty;C Robert;P Hersey;P Nathan;P Nathan

2151
Citations
Renal cell carcinoma.

James J. Hsieh;Mark P. Purdue;Sabina Signoretti;Charles Swanton

2144
Citations
Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko

1955
Citations
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M.M. Eggermont;Christian U. Blank;Mario Mandala;Georgina V. Long

1715
Citations
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko

1464
Citations
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

G. V. Long;A. Hauschild;M. Santinami;V. Atkinson

1423
Citations
Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing

Marco Gerlinger;Stuart Horswell;James Larkin;Andrew J Rowan

1336
Citations

Frequent Co-Authors

Martin Gore Royal Marsden NHS Foundation Trust

Samra Turajlic Royal Marsden NHS Foundation Trust

Georgina V. Long University of Sydney

Paolo A. Ascierto National Institutes of Health

Caroline Robert University of Paris-Saclay

Paul Lorigan University of Manchester

Dirk Schadendorf University of Duisburg-Essen

Charles Swanton The Francis Crick Institute

Grant A. McArthur Peter MacCallum Cancer Centre

Antoni Ribas University of California, Los Angeles

External Links

Personal website of James Larkin

If you think any of the details on this page are incorrect, let us know.

Related Online Degrees & Career Pathways

Exploring health-related careers in the USA goes beyond just medical school. Many students choose online degrees for flexibility, diverse specializations, and accessibility. For example, those interested in food, health, and wellness can turn to an online nutrition degree to enter fields like public health or dietetics.

Another growing area is healthcare management. Understanding how to evaluate healthcare administration degree programs is essential for aspiring leaders in hospitals, clinics, and health systems. Accreditation, curriculum, and practical experience all matter when making your choice.

Nursing is a vital pathway, with flexible options like an rn to bsn without clinicals for registered nurses who want to advance their credentials quickly from home. For those seeking advanced practice, pursuing the shortest msn to dnp program can help fast-track your journey to a doctoral degree in nursing.

By considering these alternative online degrees, you open up multiple rewarding career paths within the health and medical sector—many of which offer high demand, job security, and personal fulfillment.